Enables Whole-Transcriptome In Situ Spatial Biology with Single-Cell Sensitivity at Scale Debuts at AACR Annual Meeting 2026 with Data from Leading Research Institutions, Including the June Lab at the Perelman School of Medicine, University of Pennsylvania and German Cancer Research Institute (DKFZ) PLEASANTON, Calif., April 18, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced Atera, a new in situ spatial biology platform enginee

A trio of scientists behind the first gene therapy approved in the United States have been awarded a Breakthrough Prize in Life Sciences. It’s arguably one of the most prominent recognitions yet for the field of gene therapy, which has suffered several ups and downs during the decades-long dream of curing diseases by replacing broken genes. Jean Bennett, Albert Maguire and Katherine High shared the award, which is backed by Silicon Valley billionaires and comes with a $3 million prize, for their

ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study First head-to-head, double-blind, randomized phase 4 study powered to directly compare the tolerability profiles of these vaccines in adults in a real-world settingResults were presented today at the European Society of Clinical Microbiology and Infectious Diseases Global Congress in Munich, Germany. Paris, April 18, 2026. Sanofi's protein-based non-mRNA COVID-19 vaccine Nuvaxovid (NVX-C

Welcome back to Endpoints Weekly! Q1 earnings season is officially upon us. Max Gelman kicked off our coverage this week with a story about Johnson & Johnson’s confidence in navigating biosimilar competition to Stelara. We also covered landmark results for Revolution Medicines’ pancreatic cancer drug, a flurry of news from DC, and another acquisition for Eli Lilly. Don’t miss John Carroll’s Q1 deals report, where he dives into the numbers on recent M&A activity. We’ll be back next week! — Nicole

ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease symptoms in this underserved patient populationADAPT SERON, OCULUS, and Jr study results build on VYVGART's approved gMG indication and show its potential as the first and only biologic therapy effective across MG subtypes ADHERE post hoc analysis supports earlier use of VYVGART in treatment-naïve CIDP patients, with 87.5% achieving early benefit April 18,

Teva wins appeal in migraine patent fight with LillyICER suggests reworks to accelerated approvalBiovac brings in more than $100M to expand vaccine production facility Teva wins appeal in migraine patent fight with LillyA US appeals court has revived a patent lawsuit filed by Teva against Eli Lilly over their rival migraine drugs, reversing a prior ruling in the case. The US Court of Appeals for the Federal Circuit found that Teva's Ajovy (fremanezumab) patents were valid.The dispute dates back

GA, UNITED STATES, April 18, 2026 / EINPresswire.com / -- Chimeric antigen receptor , or CAR, therapy is no longer just a cancer story. This review shows how the field is expanding beyond conventional CAR-T cells into a wider family of engineered cell platforms, including NK cells, γδ T cells, natural killer T (NKT) cells, mucosal-associated invariant T (MAIT) cells, and double-negative T cells (DNT), regulatory T cells (Tregs), macrophages, dendritic cells, neutrophils, and stem-cell-based syst

SHANGHAI and HONG KONG, April 17, 2026 /PRNewswire/ -- Antengene Corporation Limited ( "Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that it has released present results from three novel programs in poster presentations at the 2026 American Association

기사원문 Abstract CT030: A phase 1b/2a, open-label, multicenter, randomized, dose escalation study evaluating the safety, tolerability and efficacy of RZ-001 in combination with valganciclovir (VGCV) and atezolizumab/bevacizumab in subjects with hepatocellular ca Rznomics Inc., a biotechnology company specializing in RNA-based gene therapeutics, announced that it will deliver an oral presentation on the interim Phase 1/2a clinical results for ‘RZ-001’—an RNA-based oncology candidate targeting hepato

-Efficacy and safety data shared at IMMUNOLOGY2026 reinforce potential of ZL-1503 as a first-in-class treatment for moderate-to-severe atopic dermatitis and other IL-13 and IL-31-driven diseases -Strong inhibition of both inflammatory and pruritic pathways over 112 days following a single dose of ZL-1503, together with a favorable preclinical safety profile, supports potential for less frequent dosing than current biologics -Zai Lab initiated first-in-human Phase 1/1b studies of ZL-1503 in Decem